AcroMeta Group Limited Announces Proposed Renounceable Rights cum Warrants Issue and Receives SGX Listing Notice
Key Points of the Announcement
- Proposed Rights cum Warrants Issue: AcroMeta Group Limited is undertaking a renounceable, non-underwritten rights cum warrants issue, offering up to 276,169,748 new ordinary shares (“Rights Shares”) at S\$0.016 per share.
- Bonus Warrants: Up to 92,056,582 free unlisted warrants will be issued. Each warrant entitles holders to subscribe for one new ordinary share at an exercise price of S\$0.032. The allotment is on the basis of two Rights Shares for every three existing shares held as at the Record Date.
- SGX Listing Approval: The company received the Listing and Quotation Notice (LQN) from the Singapore Exchange Securities Trading Limited (SGX-ST) on 10 June 2026. Approval was granted for the listing and quotation of up to 265,058,637 Rights Shares and 88,352,879 Warrant Shares on Catalist, subject to compliance with listing requirements and lodgement of the Offer Information Statement.
Important Information for Shareholders
- Potential Price Sensitivity: The rights issue may dilute the value of existing shares, but also provides current shareholders an opportunity to increase their holdings at a discount and benefit from potential upside via warrants.
- Completion Uncertain: The completion of the rights cum warrants issue is subject to several conditions. There is no certainty or assurance that the issue will be completed or that terms will not change.
- Investor Caution: Shareholders and investors are advised to exercise caution when dealing in AcroMeta shares. They should consult professional advisors if unsure of their actions.
- Directors’ Responsibility Statement: The Board confirms that the announcement is a full and true disclosure of all material facts related to the issue, and they are not aware of any undisclosed material facts.
- SGX-ST Disclaimer: The announcement has been reviewed by the company’s sponsor but not examined or approved by the SGX-ST, which assumes no responsibility for the contents.
Details That May Impact Share Value
- The rights issue could increase liquidity in AcroMeta’s shares and, depending on demand and market conditions, potentially move the share price.
- The exercise price for warrants (S\$0.032) is double the rights share subscription price (S\$0.016), implying potential for upside if the company’s performance improves.
- Any changes to the terms or failure to complete the issue could adversely affect investor sentiment.
- The significant capital raise may signal expansion, restructuring, or working capital needs, which are factors investors should monitor closely.
Conclusion
This announcement is potentially price-sensitive and may impact the valuation and trading activity of AcroMeta Group Limited shares. Shareholders should monitor further updates closely, as the terms, completion, and outcome of the rights cum warrants issue could materially influence the company’s capital structure and future prospects.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult financial advisors before making any investment decisions. The information herein is based on company announcements and may be subject to change.
AcroMeta集团公布可转让配售权利及认股权证发行计划并获得新加坡交易所上市通知
公告要点
- 拟议配售权利及认股权证发行： AcroMeta集团将进行可转让、非承销的配售权利及认股权证发行，预计发行最多276,169,748新普通股，每股发行价为0.016新元。
- 免费认股权证： 最多92,056,582份免费未上市认股权证。每份认股权证可认购一份新普通股，行使价为0.032新元。根据配售基准，每持有三份现有股份可配售两份权利股。
- 新交所上市批准： 公司于2026年6月10日收到新加坡交易所（SGX-ST）上市与报价通知，批准最多265,058,637份权利股及88,352,879份认股权证股份在Catalist上市，前提是符合上市要求及提交发行说明书。
股东需注意的重要事项
- 价格敏感信息： 本次配售可能稀释现有股东价值，但股东可低价增持股份，并通过认股权证分享潜在收益。
- 完成存在不确定性： 本次配售权利及认股权证发行受多项条件约束，不保证一定完成，条款也可能发生变化。
- 投资者警示： 股东及投资者在买卖AcroMeta股份时应保持谨慎，如不确定应咨询专业顾问。
- 董事责任声明： 董事会确认公告内容真实完整，没有遗漏重大事实。
- 新交所免责声明： 公告已由公司赞助商审核，但未获新交所审查或批准，新交所不对内容负责。
可能影响股价的细节
- 配售权利发行可能增加股份流动性并影响股价，具体取决于市场需求和条件。
- 认股权证行使价（0.032新元）是权利股发行价（0.016新元）的两倍，若公司业绩提升可能带来上行机会。
- 条款变更或发行未完成可能影响投资者情绪。
- 大规模融资或暗示公司扩张、重组或资金需求，投资者应高度关注。
结论
该公告具有价格敏感性，可能影响AcroMeta集团股份估值和交易活动。股东应密切关注后续动态，因为配售权利及认股权证发行的条款、完成情况及结果可能对公司资本结构和未来前景产生实质性影响。
免责声明
本文仅供信息参考，不作为投资建议。投资者应自行研究并咨询财务顾问后再作投资决策。本文信息来源于公司公告，可能随时变更。
